Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis – Nature.com

Zhang, L. & Vijg, J. Somatic mutagenesis in mammals and its implications for human disease and aging. Annu. Rev. Genet. 52, 397419 (2018).

CAS PubMed PubMed Central Article Google Scholar

Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal cells. Science 349, 14831489 (2015).

CAS PubMed Article Google Scholar

Kakiuchi, N. & Ogawa, S. Clonal expansion in non-cancer tissues. Nat. Rev. Cancer 21, 239256 (2021).

CAS PubMed Article Google Scholar

Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 24772487 (2014).

PubMed PubMed Central Article CAS Google Scholar

Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 24882498 (2014).

PubMed PubMed Central Article CAS Google Scholar

McKerrell, T. et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 10, 12391245 (2015).

CAS PubMed PubMed Central Article Google Scholar

Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 14721478 (2014).

CAS PubMed PubMed Central Article Google Scholar

Abelson, S. et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 400404 (2018).

CAS PubMed PubMed Central Article Google Scholar

Desai, P. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 24, 10151023 (2018).

CAS PubMed PubMed Central Article Google Scholar

Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111121 (2017).

PubMed PubMed Central Article Google Scholar

Dorsheimer, L. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 4, 2533 (2019).

PubMed Article Google Scholar

Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).

CAS PubMed PubMed Central Article Google Scholar

Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374382.e4 (2017).

CAS PubMed PubMed Central Article Google Scholar

Gibson, C. J. et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J. Clin. Oncol. 35, 15981605 (2017).

CAS PubMed PubMed Central Article Google Scholar

Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580584 (2018).

CAS PubMed PubMed Central Article Google Scholar

Yoshizato, T. et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N. Engl. J. Med. 373, 3547 (2015).

CAS PubMed PubMed Central Article Google Scholar

Bick, A. G. et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature 586, 763768 (2020).

CAS PubMed PubMed Central Article Google Scholar

Hinds, D. A. et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 128, 11211128 (2016).

CAS PubMed PubMed Central Article Google Scholar

Szustakowski, J. D. et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat. Genet. 53, 942948 (2021).

CAS PubMed Article Google Scholar

Fabre, M. A. et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature 606, 335342 (2022).

CAS PubMed PubMed Central Article Google Scholar

De-Morgan, A., Meggendorfer, M., Haferlach, C. & Shlush, L. Male predominance in AML is associated with specific preleukemic mutations. Leukemia 35, 867870 (2021).

PubMed Article Google Scholar

Bick, A. G. et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation 141, 124131 (2020).

CAS PubMed Article Google Scholar

Bulik-Sullivan, B. K. et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291295 (2015).

CAS PubMed PubMed Central Article Google Scholar

Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 12281235 (2015).

CAS PubMed PubMed Central Article Google Scholar

Corces, M. R. et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 11931203 (2016).

CAS PubMed PubMed Central Article Google Scholar

Finucane, H. K. et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet. 50, 621629 (2018).

CAS PubMed PubMed Central Article Google Scholar

Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44, 369375 (2012) .

CAS PubMed PubMed Central Article Google Scholar

Walsh, T. G. et al. Loss of the exocyst complex component EXOC3 promotes hemostasis and accelerates arterial thrombosis. Blood Adv. 5, 674686 (2021).

CAS PubMed PubMed Central Article Google Scholar

Astle, W. J. et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell 167, 14151429.e19 (2016).

CAS PubMed PubMed Central Article Google Scholar

Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic correlations across human complex traits. Nat. Genet. 52, 859864 (2020).

CAS PubMed Article Google Scholar

Zekavat, S. M. et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat. Med. 27, 10121024 (2021).

CAS PubMed PubMed Central Article Google Scholar

Niroula, A. et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat. Med. 27, 19211927 (2021).

CAS PubMed PubMed Central Article Google Scholar

Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics 35, 48514853 (2019).

CAS PubMed PubMed Central Article Google Scholar

Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics 32, 32073209 (2016).

CAS PubMed PubMed Central Article Google Scholar

Vsa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat. Genet. 53, 13001310 (2021).

PubMed PubMed Central Article CAS Google Scholar

Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 48, 481487 (2016).

CAS PubMed Article Google Scholar

Ragu, C. et al. The transcription factor Srf regulates hematopoietic stem cell adhesion. Blood 116, 44644473 (2010).

CAS PubMed Article Google Scholar

Zink, F. et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130, 742752 (2017).

CAS PubMed PubMed Central Article Google Scholar

Zhou, G. et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 47, W234W241 (2019).

CAS PubMed PubMed Central Article Google Scholar

Cowen, L., Ideker, T., Raphael, B. J. & Sharan, R. Network propagation: a universal amplifier of genetic associations. Nat. Rev. Genet. 18, 551562 (2017).

CAS PubMed Article Google Scholar

Fernndez-Tajes, J. et al. Developing a network view of type 2 diabetes risk pathways through integration of genetic, genomic and functional data. Genome Med. 11, 19 (2019).

PubMed PubMed Central Article Google Scholar

Tischkowitz, M. et al. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br. J. Haematol. 123, 469471 (2003).

CAS PubMed Article Google Scholar

Lim, Y. et al. Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. Sci. Transl. Med. 7, 291ra96 (2015).

PubMed PubMed Central Article CAS Google Scholar

Ostrander, E. L. et al. The GNASR201C mutation associated with clonal hematopoiesis supports transplantable hematopoietic stem cell activity. Exp. Hematol. 57, 1420 (2018).

CAS PubMed Article Google Scholar

Ghoussaini, M. et al. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic Acids Res. 49, D1311D1320 (2021).

CAS PubMed Article Google Scholar

Taylor, K. E., Ansel, K. M., Marson, A., Criswell, L. A. & Farh, K. K.-H. PICS2: next-generation fine mapping via probabilistic identification of causal SNPs. Bioinformatics 37, 30043007 (2021).

CAS PubMed Central Article Google Scholar

Farh, K. K.-H. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337343 (2015).

CAS PubMed Article Google Scholar

Bao, E. L. et al. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. Nature 586, 769775 (2020).

CAS PubMed PubMed Central Article Google Scholar

Buenrostro, J. D. et al. Integrated single-cell analysis maps the continuous regulatory landscape of human hematopoietic differentiation. Cell 173, 15351548.e16 (2018).

CAS PubMed PubMed Central Article Google Scholar

Ulirsch, J. C. et al. Interrogation of human hematopoiesis at single-cell and single-variant resolution. Nat. Genet. 51, 683693 (2019).

CAS PubMed PubMed Central Article Google Scholar

See the original post here:
Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis - Nature.com

Whitmer axes stem cell research, pregnancy center funding over abortion access concerns – MLive.com

Gov. Gretchen Whitmer used her veto pen on the states education budget Thursday to strike funding for pregnancy centers and stem cell research, saying that wording within the bill tried to create a gag rule concerning abortion.

Whitmer gave the final OK to a $19.6 billion K-12 education budget which contained an additional roughly $2 billion to universities and $530.3 million to community colleges, bringing the overall amount of the education budget to $22.2 billion July 14 at Mott Community College in Flint.

Word of her vetoes, however, came not too long after signing the budget and were targeted in two specific areas: stem cell research and crisis pregnancy centers.

RELATED: Whitmer signs $19.6B historic education budget, contains highest ever per-pupil investment

In a letter sent to lawmakers detailing the status of the final budget bill, Whitmer wrote that she was striking the items from the document as they harm womens health care.

These line items would create a gag rule preventing reproductive health-service providers from even mentioning abortion and otherwise make it harder for women to get the health care they need, she wrote. Any efforts to undermine a womans ability to make her own medical decisions with her trusted health-care provider will earn my disapproval. Women and doctors should be making health-care decisions not politicians.

Comprising her three vetoes were two $500,000 funding pots for pregnant and parenting student services, the wording for which put an explicit bar on mentioning abortion as a form of family planning, and $5 million in funding for stem cell/fetal tissue research.

Similar to the pregnancy service centers, wording surrounding the stem cell research grants would require universities agree to not conduct any research on aborted fetal tissue in order to make use of those funds.

On Friday, her administration again defended the move, with Whitmers Communication Director Bobby Leddy saying: While politicians in other states rush to restrict womens health care rights, even in instances of rape or incest, Michigan must remain a place where a womans ability to make her own medical decisions with her trusted health-care provider is respected.

The education budget signed earlier this week possesses the highest amount of per-pupil funding the state has ever allocated at $9,150 a child. Its a $450 increase per child, equaling a total cost increase of $630.5 million from the year prior. Theres also $214 in additional per-pupil funding for mental health and school safety for every child enrolled in a public school district.

More from MLive

Dixon and Rinke going tit for tat in gov. primarys final stretch

Meet the 9 Democrats vying to win the 13th U.S. House district seat

West Michigan clerk with forgery charge told not to oversee primary election

Want a say in Michigan education funding? Apply for governors parent council.

Ryan Kelley is confident he can beat Gretchen Whitmer and federal charges

View original post here:
Whitmer axes stem cell research, pregnancy center funding over abortion access concerns - MLive.com

Changing the World Through Philanthropy: UC San Diego Raises $3.05 Billion as Campaign for UC San Diego Concludes – University of California San Diego

From scholarships and fellowships to research to address the worlds greatest challenges, funds from more than 163,000 donors are making a difference locally, nationally and around the globe

The University of California San Diego has reached the conclusion of its landmark Campaign for UC San Diego, raising a total of $3.05 billion in philanthropic support over a span of 10 years. The funds have spurred a significant campus transformation, increased access with scholarships and fellowships for the next generation of leaders and expanded the universitys positive global impact with research that is addressing some of the worlds most pressing concerns.

Founded in 1960, UC San Diego is the nations youngest university to reach a multibillion-dollar fundraising goal in a single campaign, raising $1 billion more than the original $2 billion goal. More than 163,000 supporters designated charitable gifts and grants to over 450 different areas across campus, including UC San Diego Health and Scripps Institution of Oceanography. In the final year of the Campaign, which concluded on June 30, 2022, the campus raised a record-breaking $420 million, setting an upward trajectory for continued transformation and impact.

UC San Diego exceeded its initial campaign goal by more than $1 billion, raising a total of $3.05 billion.

The incredible support from our generous donors during the Campaign for UC San Diego has fueled a remarkable physical, intellectual and cultural transformation that has greatly enhanced the experiences of our students, our patients and our greater San Diego community, in addition to benefiting countless lives around the globe, said Chancellor Pradeep K. Khosla. Belief in UC San Diego as a force for change gave us three billion new reasons to keep exploring, to keep discovering and to keep impacting the world around us.

Campaign for UC San Diego volunteer leadership played a critical role in the success of the Campaign. Honorary co-chairs Joan and Irwin Jacobs, Ernest Rady and T. Denny Sanford set the foundation for the Campaigns success with gifts including $100 million from the Jacobs to establish the Jacobs Medical Center at UC San Diego Health, a commitment of $100 million from Ernest and Evelyn Rady for the Rady School of Management, and $200 million in total funds from Sanford to establish both the Sanford Stem Cell Clinical Center at UC San Diego Health and the T. Denny Sanford Institute for Empathy and Compassion.

In addition, more than 100 alumni and community members stepped up to lead this historic effort as members of the Campaign for UC San Diego Cabinet. Every cabinet member donated to the Campaign, generating support totaling $1 billion. More than half of the cabinet was composed of alumni, including cabinet co-chairs Ken Kroner, PhD 88, and Aryeh Bourkoff 95, who each supported the Campaign with multimillion-dollar gifts. Many members of the Cabinet are also current or former trustees of the UC San Diego Foundation.

Overall, alumni giving also went up significantly. More than 45,600 alumni donors gave $257 million in gifts, representing an increase of 1,300% over the last campaign.

We are so incredibly proud of how UC San Diego alumni have come together over the past decade to support their alma mater as a collective group, said Kimberley Phillips Boehm 82, UC San Diego Alumni president from 2020-22. This support is driving the universitys upward trajectory as it makes a difference for future generations of students, spurs innovative research, enhances medicine and transforms our campus.

Itzel Guadalupe Jimenez Jimenez 25, a Karen and Jeff Silberman Chancellors Associates Scholar, hopes to pursue a career in health care.

A key priority of the Campaign for UC San Diego was supporting its outstanding undergraduate and graduate students. The campus raised approximately $378 million for student support and success during the course of the Campaign, creating 315 new scholarship funds, including 163 endowed scholarships, which will remain in perpetuity. In addition, 184 new graduate fellowship funds were established, including 66 endowed fellowships.

A vital program established during the Campaign for UC San Diego was the Chancellors Associates Scholars Program (CASP). In addition to providing full tuition, fees and housing for high-achieving students from underrepresented communities, the program supports students with a wide range of services and opportunities to ensure that they thrive on campus and are fully engaged in academics, student life and in university experiences. Supported by $8 million in private support, the scholarship has been awarded to more than 1,800 students.

Itzel Guadalupe Jimenez Jimenez 25, a Karen and Jeff Silberman Chancellors Associates Scholar and Lincoln High School graduate, chose to major in Spanish literature, recalling a childhood memory of being in an emergency room while her mother struggled to overcome language barriers. She plans to pursue a career as a translator in the health care industry with the goal of helping all patients get the care they need.

The Chancellors Associates Scholarship has given me a chance to study and pursue my dream career, said Jimenez Jimenez. Receiving this scholarship really means a lot to me because it is one less thing my family has to worry about.

Jacobs Fellow Marwa Abdalla is a doctoral candidate focused on anti-Black and anti-Muslim racisms.

In 2021, Chancellor Khosla announced the Chancellors Scholarship and Fellowship Challenge to boost funding for students on campus. Gifts to undergraduate scholarships, graduate fellowships and health-related professional school scholarships were matched 1:2 by the chancellor. At the close of the challenge, a total of $21 million was raised in gifts and matching funds.

Jerri-Ann and Gary E. Jacobs 79, pledged a total of $2 million to student support as part of the challenge, including adding $1 million to the existing Jerri-Ann and Gary E. Jacobs Endowed Fellowship Fund. Jacobs Fellow Marwa Abdalla is a second-year doctoral candidate in the Department of Communication whose research is focused on anti-Black and anti-Muslim racisms, media representations of Islam and Muslims, and how legacies of imperialism and Orientalism continue to inform conservative and progressive politics.

Not only is it an honor to be recognized with this fellowship, said Abdalla, but the support allows me to focus on connecting my research to national and local efforts aimed at challenging racism in all its forms.

In addition, several other alumni donors have supported undergraduate scholarships at UC San Diegooften with the goal of boosting equity, diversity and inclusion on campus. Kimberley Phillips Boehm 82 and Marcus Boehm 83 donated $1 million to support the PATHways to STEM through Enhanced Access and Mentorship Program (PATHS), which is structured to provide critical mentorship and financial support for undergraduate UC San Diego STEM students from under-resourced communities.

UC San Diego received the largest scholarship gift for scholar-athletes in its history from LionTree, an independent investment and merchant bank founded by alumnus and Campbain Cabinet co-chair Aryeh Bourkoff.

UC San Diego also received the largest scholarship gift for scholar-athletes in its history from independent investment and merchant bank LionTree, which was founded by alumnus Aryeh Bourkoff. RIMAC Arena was renamed LionTree Arena in recognition of the gift.

To learn more about the Campaigns remarkable impact on student support and success, such as contributions to the Triton Food Pantry and more, visit the Campaign website to read about other student support gifts.

Fueled by philanthropic support, UC San Diego ranked 4th among public research institutions in the U.S. by Nature Index for high-quality science, based on research publications in highly selective science journals in 2020. The campus ranked 10th among all U.S. universities. Research is driving innovation and discoveries in a wide range of areas at UC San Diego, from exploring active genetics as a means to control malaria worldwide to developing actionable strategies for adapting to climate change.

Kicking off the public phase of the Campaign for UC San Diego in 2017, alumnus Taner Halcolu 96 committed $75 million to launch the Halcolu Data Science Institute (HDSI) and support data science initiatives on campus. Within the first year, the institute established itself as one of the largest academic data science programs in the nation.

Looking to the sky, scientists are closer to understanding the conditions of the universe moments after its inception, thanks to commitments totaling nearly $100 million from the Simons Foundation over the course of the Campaign. The funds supported design, construction and operations of the Simons Observatory in Chiles Atacama Desert.

The Goeddel Family Technology Sandbox is providing access and training to master leading-edge biotech industry instruments.

In the UC San Diego School of Social Sciences, researchers are working to better understand and address the factors that lead to homelessness. With philanthropic support from Phyllis and Dan Epstein and Hanna and Mark Gleiberman, UC San Diego recently launched the regions first large-scale, university-based research and data hub focused exclusively on homelessness. The Homelessness Hub at UC San Diego will serve as a non-partisan hub for research, education, policy and action on homelessness.

Philanthropic support like this from the Epsteins and Gleibermans is helping drive a wide range of critical work in the social sciencesfrom homelessness to immigration and racial inequitythat benefit our society now and will shape the future for generations to come, said Dean of the School of Social Sciences Carol Padden.

Alumnus David Goeddel 72, and his wife, Alena, established the Goeddel Family Technology Sandbox with a $7.5 million gift. The new, innovative campus facility, also part of a 10-year public-private partnership with Thermo Fisher Scientific, is designed to help set UC San Diego graduates ahead in the biotech industry, providing them with access and training to master leading-edge industry instruments which are often cost-prohibitive for college campuses. The Sandbox will drive research, education and innovation in emerging areas including genome engineering, mass spectrometry, flow cytometry, light microscopy, cryo-electron microscopy (cryo-EM) and data science.

The Goeddel Family Technology Sandbox will further enhance UC San Diegos profile as one of the nations top places to study the biological sciences and as the top producer of talent to fuel innovation in life sciences in both academia and industry, said Dean of the School of Biological Sciences Kit Pogliano.

The Joe and Clara Tsai Foundation provided a major gift to the 21st Century China Center at the School of Global Policy and Strategy (GPS) to expand its data-based research, policy engagement and education on U.S.-China relations. The largest donation ever received by GPS and its research centers, the gift provided an endowment that helped cement the center as the leading U.S. academic center and policy think tank that produces scholarly research and informs policy discussions related to China.

The Center for Climate Change Impacts and Adaptation is addressing the effects of climate change, such as flooding in Imperial Beach.

The Center for Climate Change Impacts and Adaptation, created in 2015 with a $5 million commitment from Richard and Carol Dean Hertzberg, is focused on a new chapter of climate research that considers how society can address the consequences of climate change that are already unfolding. The center draws on the expertise of climate scientists as well as experts ranging from economists, sociologists and engineers to urban planners and political scientists to document climate change impacts and devise practical solutions.

In 2017, the late Franklin Antonio 74, became the first alumnus to have a building named in his honor after making a $30 million gift to support the Jacobs School of Engineering. Franklin Antonio Hall, a 200,000-square-foot engineering building will open in fall of 2022. The building will feature 13 collaboratoriesspaces that will house multiple professors and their respective research groups to encourage interdisciplinary collaborations to address some of societys most critical issues.

As UC San Diego drives leading-edge innovation and discoveries, the Institute for Practical Ethics was established in the School of Arts and Humanities with $1 million from Joel and Ann Reed to help close the gap between the pace of innovation and societys ability to deal with these advances responsibly.

The Bill & Melinda Gates Foundation granted $1.4 million to study next-generation gene drive systems based on CRISPR technology, which could potentially be used to curb the spread of mosquito-borne pathogens such as malaria. The funding was also designated to help address the social and ethical challenges of moving these techniques from the lab into the wild. In total, the Gates Foundation has provided nearly $62 million in total grant funding over the course of the Campaign to a wide range of campus areas including public health, medicine and education.

During the course of the Campaign, 123 new endowed faculty chairs were established. Increasing the number of endowed chairs is a priority at UC San Diego, as they provide a perpetual source of funds for research and scholarly work by chair-holders, playing an important role in attracting and retaining academic leaders. The effort to grow the number of endowed chairs on campus was bolstered by the UC San Diego Chancellors Endowed Chair and Faculty Fellowship Challenge, wherein Chancellor Khosla matched $500,000 eligible endowed chair gifts. A University of California-sponsored Presidential Match for Endowed Chairs was launched in 2014 and helped grow support for endowed chairs even further. Endowed chairs were created throughout campus including the Dr. Harry M. Markowitz Endowed Chair in Finance and Investing and the Duane A. Nelles Jr. Endowed Chair in Corporate Governance at the Rady School of Management, the Conrad Prebys Presidential Chair in Music, the Edward A. Frieman Presidential Chair in Climate Sustainability and many more.

To learn more about the groundbreaking research and innovation taking place thanks to the support of philanthropic partnersfrom the depths of the ocean to the universe above, please visit the Campaign for UC San Diego website.

UC San Diego Health is dedicated to advancing medicine through breakthrough discoveries, including pioneering firsts in surgery, imaging, cancer treatment and cardiovascular care. UC San Diego Health is ranked 1st in San Diego and 5th in California for health care by U.S. News & World Report, positioning it among the nations best hospitals.

During the Campaign, UC San Diego Health went through an immense transformation and expansion. Science research was bolstered by the 2014 opening the Altman Clinical and Translational Research Institute, which translates scientific discoveries into drugs and therapies. Jacobs Medical Center then opened in 2016, followed in 2018 by the Koman Family Outpatient Pavilion, which includes eight surgery suites, basic and advanced imaging, physical therapy and pain management plus infusion and apheresis services.

Jacobs Medical Center at UC San Diego Health opened in 2016.

Over the last decade, UC San Diego Health has undergone a tremendous transformation that has benefited patients throughout the region with enhanced treatments and better facilities, said UC San Diego Health CEO Patty Maysent. We are so grateful to our donors who have generously partnered with us in providing the best possible care for patients, from building the leading-edge facilities to recover and heal, to offering new and innovative treatments of promise.

Thanks to the support of Irwin and Joan Jacobs, as well as many other generous donors, Jacobs Medical Center has now served the community with specialty patient care for over five years. It is home to the A. Vassiliadis Family Pavilion for Advanced Surgery, the Pauline and Stanley Foster Pavilion for Cancer Care and the Rady Pavilion for Women and Infants.

Alumnus Aaron Sathrum, MS 06, PhD 11, can attest to the impact of the care available at Jacobs Medical Center. All three of his children were born at the facility, but his youngest son, Niels, was born at only 26 weeks in the medical centers Rady Pavilion for Women and Infants. Niels was only 2.2 pounds and suffered from collapsed lungs, an intestinal perforation, a brain hemorrhage, jaundice and a blood infection.

The challenges ahead were great, but with a treatment plan in place, the help of the Jacobs Medical Center team and the resilience of our son, we were released earlier than expected, said Sathrum. Although we spent over half of the year in the hospital, unsure of what was to come next, there is no better feeling than knowing our family is together.

All three of the Sathrum familys children were born at Jacobs Medical Center.

Niels is now over a year old. Every day I look at himIm grateful, said Sathrum.

During the Campaign for UC San Diego, many donors helped advance treatments for cancer. Centers and research initiatives established at UC San Diego Health included the Hanna and Mark Gleiberman Head and Neck Cancer Center, the Dean-Hertzberg Breast Cancer Database System (BCDS) at Moores Cancer Center and the Comprehensive Breast Health Center supported by Rebecca Moores. As a result, patients are better equipped with leading-edge technologies and treatments to overcome cancer.

In addition, donors came together to support ocular health and fight eye disease and blindness. Andrew J. Viterbi gave $50 million to name the Viterbi Family Department of Ophthalmology and the Viterbi Family Vision Research Center, which also created six new endowed faculty chairs. The Nixon Visions Foundation, led by UC San Diego alumnus Brandon Nixon 85, and his wife, Janine, established the Nixon Visions Foundation Macular Dystrophy-PRPH2 Research Fund to treat macular dystrophy, a condition for which there is no cure. And, continuing her decades-long legacy of support for eye health, Darlene Shiley gave $10 million for the clinical space expansion of the Shiley Eye Institute at UC San Diego Health, which will bring a new era of vision care and research with increased clinical capacity and research infrastructure.

The Campaign also ushered in a new era of public health research, education and advances with a $25 million gift from the Dr. Herbert and Nicole Wertheim Family Foundation that established the Herbert Wertheim School of Public Health and Human Longevity Science. The Herbert Wertheim School of Public Health is working to promote healthier populations on a local, national and global scale.

Daniel and Phyllis Epstein also recently established the Epstein Family Alzheimers Research Collaborative at UC San Diego and USC, with $25 million going to each institution to spark new collaborative efforts to discover effective therapies for Alzheimers disease.

Philanthropic funds are fueling advancements in treatments and cures for disease that will ultimately benefit people around the world.

Establishing endowed faculty chairs was a key priority of the campaign, with 40 created in the health sciences. Iris and Matthew Strauss, longtime supporters of cancer research and patient care at Moores Cancer Center at UC San Diego Health established the Iris and Matthew Strauss Chancellors Endowed Chair in Head and Neck Surgery to support excellence in research, education and clinical care.

Endowed faculty chairs play a critical role in helping to attract and retain the top minds in science and medicine, said Steven Garfin, MD, interim vice chancellor for Health Sciences and interim dean of the UC San Diego School of Medicine. We are so grateful to our donors who have supported UC San Diego in the discovery and development of better treatments and new cures for devastating diseases and medical conditions.

Looking to the future, Price Philanthropies Foundation and the Price family donated $10 million to support a new 250,000-square-foot outpatient pavilion at the UC San Diego Medical Centers Hillcrest campus, which is currently undergoing revitalization. The outpatient pavilion is anticipated to open in 2025.

To read more about the incredible medical advancements made possible with philanthropy, including those to battle conditions such as Parkinsons, traumatic brain injury and more, please visit the Campaign for UC San Diego website.

Over the last decade, UC San Diego has undergone a significant physical, intellectual and cultural transformation, with the goal of becoming a premier destination for students, employees, patients and community members. In 2016, construction started on the 11-mile extension of the UC San Diego Blue Line trolley. When two new trolley stations opened on campus in 2021, the university became connected to the region like never before, and donors have stepped up to help open the campus more broadly to the region.

UC San Diego Park & Market, the universitys long anticipated presence in downtown San Diego opened earlier this year.

In addition to supporting research to address Alzheimers disease and homelessness, Daniel and Phyllis Epstein provided $10 million for the soon-to-be-opened Epstein Family Amphitheater. The new state-of-the-art 2,850-seat campus venue, which is steps from the Central Campus station of the UC San Diego Blue Line trolley, will open in October 2022, showcasing everything from classical performances and theatrical dance to rock concerts.

Steps away from the Blue Line trolleys downtown stop is UC San Diego Park & Market, which opened in spring of 2022. Located on a full city block at the intersection of Park Boulevard and Market Street in San Diegos East Village neighborhood, Park & Market is a social and intellectual hub for civic engagement, learning and collaboration for the entire community.

Longtime UC San Diego donor Malin Burnham and his wife, Roberta, committed $3 million to support the partnership between the Burnham Center for Community Advancement and UC San Diego in their creation of a civic collaboratory at Park & Market focused on bringing together great minds to advance the region. David and Claire Guggenheim also gave $1 million to the project, establishing their namesake David and Claire Guggenheim Theatre, a 225-seat black box theater to be used for a wide range of performances and teaching.

The internationally renowned Stuart Collection at UC San Diego also received a $1 million gift from Mary Looker, which established an endowment to help foster the growth of the self-supported collection for years to come. Composed of 22 unique works which have been sprouting across campus over the past four decades, the Stuart Collection represents an impressive assemblage of public art by celebrated contemporary artists such as Robert Irwin, Do Ho Suh, Bruce Nauman and Kiki Smith.

Fallen Star by Do Ho Suh is a part of the unique Stuart Collection, which received $1 million in endowment support.

The arts are deeply rooted in the identity of our university, from our internationally recognized arts departments and highly-ranked degree programs to our affiliations with world-renowned artistic partners, said Executive Vice Chancellor Elizabeth H. Simmons. We are grateful to our generous donors who have helped us build upon our traditions of aesthetic experimentation and public engagement, establishing our campus as an arts destination and making us a leader amongst our peer institutions.

In support of the UC San Diego Library, which is widely utilized by the local community, UC San Diego Foundation trustee and alumna Sally T. WongAvery 75 donated $10 million through the Avery-Tsui Foundation to support East Asian scholarship and collections. In recognition of the gift, UC San Diego renamed its Biomedical Library as the Sally T. WongAvery Library. In addition, thanks to a $3 million lead donation from the late Audrey Geisel, UC San Diegos iconic Geisel Library is getting a much-needed interior update to enhance the user experience with modern, collaborative spaces.

Furthering the universitys impact in the community and changing the way education is delivered to students living in underserved areas, Robert and Allison Price, through Price Philanthropies, donated $6 million in 2015 to UC San Diegos Birch Aquarium at Scripps Institution of Oceanography to establish the Price Philanthropies Ocean Science Education Fund. The endowment created a new education program to inspire student engagement in science and interest in STEM fields, as well as to provide a blueprint for how teachers, informal science educators and scientists can work together to transform science education.

The Price Philanthropies Ocean Science Education Fund is supporting science education programs at Birch Aquarium at Scripps Institution of Oceanography.

To read more about the Campaign for UC San Diego and the incredible impact of our donors generous gifts over the last decade, please visit the Campaign for UC San Diego website.

Go here to read the rest:
Changing the World Through Philanthropy: UC San Diego Raises $3.05 Billion as Campaign for UC San Diego Concludes - University of California San Diego

Subang Jaya Medical Centre Applauded by Frost & Sullivan for Its Leadership Position in the Malaysian Hospital Industry – Canada NewsWire

SJMC is well positioned to drive the private hospital space into its next growth phase, capturing market share and sustaining its leadership in the coming years.

SAN ANTONIO, July 12, 2022 /CNW/ --Recently, Frost & Sullivan researched the Malaysian hospital industry and, based on its analysis results, recognizes Subang Jaya Medical Centre(SJMC) with the 2022 Company of the Year Award. The company is accredited by Joint Commission International (JCI) and the Malaysian Society for Quality in Health (MSQH), and its medical laboratories are certified by the International Organization for Standardization (ISO). As part of the Ramsay Sime Darby Health Care Group, SJMC ensures its medical practitioners and administrative staff provide top-notch private healthcare. The multi-disciplinary private healthcare service provider has a capacity of 444 beds, a long history, and remarkable milestones, all contributing to its leadership position in Malaysia's medical industry. SJMC is the first to conduct the following in Malaysia:

SJMC's vision involves developing partnerships to provide the best private healthcare to help patients lead better lives. The company connects deep-seated domain and operational knowledge with advanced services to deliver care during the COVID-19 pandemic. The hospital adapts real-time reverse transcription polymerase chain reaction tests to reduce the waiting time for patient admission. With Home Connect, home care services are available to patients who cannot commute to the hospital, either because of the difficulty in physically commuting or as a precaution against COVID-19. The service allows nurses or physiotherapists to visit patients in their homes, especially after surgery. In addition, the service includes home delivery of long-term medication. The hospital's Home Connect service is convenient and creates a shift in modern healthcare because it complies with clinical care standards, and provides patients and their families with peace of mind.

According to Siddharth Shah, Research Manager for Frost & Sullivan, "SJMC seamlessly assimilates into the post-pandemic private medical care scene and emerges as a leader in providing contactless home care as a permanent mode of care delivery, an extensive offering unique to the market."

SJMC's selected rehabilitation services, such as physiotherapy and palliative care, are available for home care visits. Its teleconnect center provides 24-hour convenience of obtaining medical advisory services over the phone or through WhatsApp to improve customer service. Moreover, the hospital became the first in the country to offer the latest tomography services for efficient and high-precision cancer treatment as well as digital PET/CT services. It conducts nursing training initiatives to prevent errors in medication and intravenous care, uphold therapy and medication safety standards, and support the continuous development of its healthcare staff. SJMC has a leadership legacy; therefore, its compelling value proposition underpins its sustained success. The company's brand equity, unwavering focus on leadership, best practices implementation, customer-centric focus, and continual and proactive innovation contribute to its sustained success and leading market position.

"SJMC meets with patients to assess their specific needs and develop tailored solutions with roadmaps for seamless execution. This foundational approach establishes ongoing trust with customers for long-lasting relationships extending throughout the service lifecycle," explained Azza Fazar, Best Practices Research Analyst for Frost & Sullivan. "The company remains a trusted partner, earning a reputation for offering the overall best care in the hospital space."

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analystscompare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Kala Mani. S. P: +603-2023 2037 E: [emailprotected]

About Subang Jaya Medical Centre

The hallmarks that determine the provision of excellent healthcare are the breadth and depth in clinical expertise and the latest in medical technology, top-notch or trail-blazing services, integrated healthcare for end-to-end patient care, high survival rates, best patient safety practices, internationally recognized accreditation, high calibre and well-trained staff and vibrant patient support group activities.

All the above and more is what made Subang Jaya Medical Centre, an award-winning multi-disciplinary and tertiary care private hospital with over 400 beds, a well-trusted and one of Asia-Pacific's most formidable standard-bearers for quality care for well over a quarter of a century since 1985.

SJMC is nestled in the bustling city of Subang Jaya in Selangor Darul Ehsan, a 30-minute drive to the Kuala Lumpur city centre and the Kuala Lumpur International Airport via major highways. Subang Jaya is one of Malaysia's largest cities, in terms of population and economic activity. SJMC provides comprehensive and complex care in all specialties and is a tertiary referral hospital, receiving local patient referrals from within Malaysia as well as international patients from the Asia-Pacific region.

Subang Jaya Medical Centre 1 Jalan SS12/1A Subang Jaya 47500 Selangor Darul Ehsan Malaysia

T: +6 03 5639 1212 (24-hour Careline) WhatsApp: +6 019 317 1818 (for appointment) E: [emailprotected] Website: http://www.subangjayamedicalcentre.com

SOURCE Frost & Sullivan

See the rest here:
Subang Jaya Medical Centre Applauded by Frost & Sullivan for Its Leadership Position in the Malaysian Hospital Industry - Canada NewsWire

Endometriosis in Teens: Causes, Symptoms, and Treatment – Healthline

Endometriosis is a condition that can occur when tissue that is normally found lining the uterus, known as the endometrium, begins to grow outside of that organ. With this disorder, the tissue can be found growing around other nearby organs the ovaries, intestines, and even tissue that lines your pelvis.

Because endometrial tissue is affected by hormonal changes during the menstrual cycle, its not uncommon for people with endometriosis to experience pain and discomfort just like they would with endometrial tissue in the uterus. And just like that tissue, this tissue breaks down too but isnt expelled.

As a result, endometriosis can lead to the growth of scar tissue, irritation, and even infertility. But while much is known about endometriosis in adult women, the condition isnt as well-researched in children or adolescents.

Officially, there is no known cause of endometriosis regardless of the age at which its discovered. And almost all researchers agree that limited studies in younger age groups, as well as healthcare professionals delaying diagnosis by several years, can contribute to its progression that often leads to infertility and other negative outcomes.

There are a few theories that highlight potential reasons, but no theory has proven to be conclusive yet. Well take a closer look at the best supported theories to-date:

Retrograde menstruation is a condition in which blood that is expelled from the uterus flows back toward the fallopian tubes rather than out of the body through the vagina. This scenario is more common than you may expect, with roughly 90% of women experiencing it at some point during their menstruating lives.

But for some, this backflow can lead to endometrial cells adhering to organs or cavity tissues, or whats known as endometrial lesions. This is why it is currently considered a key factor in developing endometriosis.

A 2013 study conducted in Japan found a link between the incidence of menstrual pain and the need for medical interventions. While the study found that roughly a third of all menstruating Japanese women experienced pain significant enough to require medication, of that group, 6% did not experience any improvement after taking medication.

More importantly, this study found that roughly 25 to 38% of adolescents that complained of chronic pelvic pain were later diagnosed with endometriosis. Meanwhile, the most common solution offered to adolescents is pain medications, which will not treat the cause of the pain.

That same 2013 Japanese study noted that some respondents were diagnosed with endometriosis while having never menstruated (premenarchal). This discovery has encouraged researchers to consider that other underlying mechanisms might contribute to endometriosis rather than retrograde menstruation.

Some researchers further hypothesized that endometriosis diagnoses in premenarchal participants could be caused by stem cells that later develop into endometrial tissue and are later activated when menstruation begins.

While we often think of endometriosis as a condition exclusively impacting women, the reality is that it can also develop in nonbinary or transmasculine (people assigned female at birth that later transition to boys) adolescents as well.

A 2020 study reviewed previous research that focused on 35 trans participants ages 26 and younger that were diagnosed with dysmenorrhea (or menstruation-related pain) and treated for that condition. Of the 35, seven of the patients were evaluated and found to have endometriosis some of which were diagnosed after transitioning and included one participant that had already begun testosterone treatment.

Of the seven patients, treatment varied from oral contraceptives, testosterone treatment, and other drugs such as danazol and progestins. The study found that results were mixed. While some respondents found success with testosterone therapy for resolving symptoms, this wasnt the case for everyone.

Ultimately, the study recommended that trans masculine people experiencing dysmenorrhea symptoms should be screened for endometriosis, and that testosterone therapy alone isnt necessarily a complete solution.

Although less is known about endometriosis in adolescent or teenage populations, symptoms tend to be consistent with those found in adult women. These include:

If you or your child is experiencing symptoms of endometriosis, keep reading to learn about getting diagnosed.

Consistently, the research and medical communities agree that early detection of endometriosis is the best way to prevent acute spread which can lead to infertility. Checking for endometriosis on your own is not possible. But letting your doctor know that youre experiencing chronic pelvic pain, heavy or long periods, or any of the other common symptoms associated with endometriosis is important.

Your physician might start the diagnostic process by performing a pelvic ultrasound to ensure that any other underlying conditions or infections arent causing your symptoms. Usually, endometriosis is diagnosed with laparoscopy. This is a minimally invasive procedure where your physician inserts a thin tube with a light and lens through a small incision into the lower abdomen. With this procedure, they can look for endometrial lesions to determine if endometriosis is present.

Unfortunately, its common for period pain to be dismissed as a regular part of life, and for many people it can take more than a decade to receive a proper diagnosis. If this is the case for you, dont hesitate to advocate for yourself and seek a second opinion if youre unable to find a treatment plan that works for you.

Currently, there is no cure for endometriosis. However, just as in adults, the goal of treating adolescent endometriosis is to control and prevent disease progression, provide symptom relief, and preserve fertility.

Several treatment methods may be recommended depending on the amount of endometrial tissue that is present (disease progression).

Treatment options can center on hormonal therapy to control estrogen levels a key factor that influences endometrial growth. For some patients, this might include taking oral contraception, or a progestin-only agent to prevent or minimize the onset of periods, as well as nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management.

Be aware that you might need to try several different types of hormonal therapies before you find the right option that controls your condition.

Some patients might also be prescribed Gonadotropin-releasing hormone (GnRH) agonist therapy. But this is usually reserved for adults, because research suggests that this treatment can impact bone mineralization in adolescents.

Surgery is often used for both diagnosis and treatment. While some surgeries can remove endometrial lesions, this is not a permanent solution for everyone.

Research has proven that even with surgery, endometrial lesions can return.

Most endometriosis conversations center around female patients. But its important to remember that trans men as well as those born male are also at risk of developing this disease.

Once thought to only be an issue for menstruating females, research suggests that endometriosis can also be detected in premenarchal youth.

Theres no cure for endometriosis. But experts, advocates, and the medical community agree that early interventions for the condition are critical for limiting its spread, controlling symptoms that can impact everyday life, and preserving fertility especially in adolescents.

Original post:
Endometriosis in Teens: Causes, Symptoms, and Treatment - Healthline

Deconstructing the mechanics of bone marrow disease | Penn Today – Penn Today

Fibrosis is the thickening of various tissues caused by the deposition of fibrillar extracellular matrix (ECM) in tissues and organs as part of the bodys wound healing response to various forms of damage. When accompanied by chronic inflammation, fibrosis can go into overdrive and produce excess scar tissue that can no longer be degraded. This process causes many diseases in multiple organs, including lung fibrosis induced by smoking or asbestos, liver fibrosis induced by alcohol abuse, and heart fibrosis often following heart attacks. Fibrosis can also occur in the bone marrow, the spongy tissue inside some bones that houses blood-producing hematopoietic stem cells (HSCs) and can lead to scarring and the disruption of normal functions.

Chronic blood cancers known as myeloproliferative neoplasms (MPNs) are one example, in which patients can develop fibrotic bone marrow, or myelofibrosis, that disrupts the normal production of blood cells. Monocytes, a type of white blood cell belonging to the group of myeloid cells, are overproduced from HSCs in neoplasms and contribute to the inflammation in the bone marrow environment, or niche. However, how the fibrotic bone marrow niche itself impacts the function of monocytes and inflammation in the bone marrow was unknown.

Now, a collaborative team from Penn, Harvard, the Dana-Farber Cancer Institute (DFCI), and Brigham and Womens Hospital has created a programmable hydrogel-based in vitro model mimicking healthy and fibrotic human bone marrow. Combining this system with mouse in vivo models of myelofibrosis, the researchers demonstrated that monocytes decide whether to enter a pro-inflammatory state and go on to differentiate into inflammatory dendritic cells based on specific mechanical properties of the bone marrow niche with its densely packed ECM molecules. Importantly, the team found a drug that could tone down these pathological mechanical effects on monocytes, reducing their numbers as well as the numbers of inflammatory myeloid cells in mice with myelofibrosis. The findings are published in Nature Materials.

We found that stiff and more elastic slow-relaxing artificial ECMs induced immature monocytes to differentiate into monocytes with a pro-inflammatory program strongly resembling that of monocytes in myelofibrosis patients, and the monocytes to differentiate further into inflammatory dendritic cells, says co-first author Kyle Vining, who recently joined Penn.More viscous fast-relaxing artificial ECMs suppressed this myelofibrosis-like effect on monocytes. This opened up the possibility of a mechanical checkpoint that could be disrupted in myelofibrotic bone marrow and also may be at play in other fibrotic diseases. Vining will be appointedassistant professor of preventive and restorative sciences in theSchool of Dental Medicine and the Department of Materials Sciences in theSchool of Engineering and Applied Science, pending approval by Penn Dental Medicines personnel committees and the Provosts office.

Vining worked on the study as a postdoctoral fellow at Harvard in the lab of David Mooney. Our study shows that the differentiation state of monocytes, which are key players in the immune system, is highly regulated by mechanical changes in the ECM they encounter, says Mooney, who co-led the study with DFCI researcher Kai Wucherpfennig. Specifically, the ECMs viscoelasticity has been a historically under-appreciated aspect of its mechanical properties that we find correlates strongly between our in vitro and the in vivo models and human disease. It turns out that myelofibrosis is a mechano-related disease that could be treated by interfering with the mechanical signaling in bone marrow cells.

Mooney is also the Robert P. Pinkas Family Professor of Bioengineering at Harvard and leads the Wyss Institutes Immuno-Materials Platform. Wucherpfennig is director of DFCIs Center for Cancer Immunotherapy Research, professor of neurobiology at Brigham and Harvard Medical School, and an associate member of the Broad Institute of MIT and Harvard. Mooney, together with co-senior author F. Stephen Hodi, also heads the Immuno-engineering to Improve Immunotherapy (i3) Center, which aims to create new biomaterials-based approaches to enhance immune responses against tumors. The new study follows the Centers road map. Hodi is director of the Melanoma Center and The Center for Immuno-Oncology at DFCI and professor of medicine at Harvard Medical School.

The mechanical properties of most biological materials are determined by their viscoelastic characteristics. Unlike purely elastic substances like a vibrating quartz, which store elastic energy when mechanically stressed and quickly recover to their original state once the stress is removed, slow-relaxing viscoelastic substances also have a viscous component. Like the viscosity of honey, this allows them to dissipate stress under mechanical strain by rapid stress relaxation. Viscous materials are thus fast-relaxing materials in contrast to slow-relaxing purely elastic materials.

The team developed an alginate-based hydrogel system that mimics the viscoelasticity of natural ECM and allowed them to tune the elasticity independent from other physical and biochemical properties. By tweaking the balance between elastic and viscous properties in these artificial ECMs, they could recapitulate the viscoelasticity of healthy and scarred fibrotic bone marrow, whose elasticity is increased by excess ECM fibers. Human monocytes placed into these artificial ECMs constantly push and pull at them and in turn respond to the materials mechanical characteristics.

Next, the team investigated how the mechanical characteristics of stiff and elastic hydrogels compared to those in actual bone marrow affected by myelofibrosis. They took advantage of a mouse model in which an activating mutation in a gene known as Jak2 causes MPN, pro-inflammatory signaling in the bone marrow, and development of myelofibrosis, similar to the disease process in human patients with MPN. When they investigated the mechanical properties of bone marrow in the animals femur bones, using a nanoindentation probe, the researchers measured a higher stiffness than in non-fibrotic bone marrow. Importantly, we found that the pathologic grading of myelofibrosis in the animal model was significantly correlated with changes in viscoelasticity, said co-first author Anna Marneth, who spearheaded the experiments in the mouse model as a postdoctoral fellow working with Ann Mullally, a principal investigator at Brigham and DFCI, and another senior author on the study.

An important question was whether monocytes response to the mechanical impact of the fibrotic bone marrow niche could be therapeutically targeted. The researchers focused on an isoform of the phosphoinositide 3-kinase (PI3K)-gamma protein, which is specifically expressed in monocytes and closely related immune cells. PI3K-gamma is known for regulating the assembly of a cell-stiffening filamentous cytoskeleton below the cell surface that expands in response to mechanical stress, which the team also observed in monocytes encountering a fibrotic ECM. When they added a drug that inhibits PI3K-gamma to stiff elastic artificial ECMs, it toned down their pro-inflammatory response and, when given as an oral treatment to myelofibrosis mice, significantly lowered the number of monocytes and dendritic cells in their bone marrow.

This research opens new avenues for modifying immune cell function in fibrotic diseases that are currently difficult to treat. The results are also highly relevant to human cancers with a highly fibrotic microenvironment, such as pancreatic cancer, says Wucherpfennig.

Adapted from a press release written by Benjamin Boettner of the Wyss Institute for Biologically Inspired Engineering at Harvard University.

Other authors on the study are Harvards Kwasi Adu-Berchie, Joshua M. Grolman, Christina M. Tringides, Yutong Liu, Waihay J. Wong, Olga Pozdnyakova, Mariano Severgnini, Alexander Stafford, and Georg N. Duda.

The study was funded by the National Cancer Institute of the National Institutes of Health (Grant CA214369), National Institute of Dental & Craniofacial Research of the National Institutes of Health (grants DE025292 and DE030084), Food and Drug Administration (Grant FD006589), and Harvard University Materials Research Science and Engineering Center (Grant DMR 1420570).

See the original post:
Deconstructing the mechanics of bone marrow disease | Penn Today - Penn Today

Stem Cell Therapy Global Market Opportunities And Strategies To 2031 – Yahoo Finance

ReportLinker

provides the strategists; marketers and senior management with the critical information they need to assess the global stem cell therapy market as it emerges from the COVID 19 shut down. Description:

New York, July 11, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Stem Cell Therapy Global Market Opportunities And Strategies To 2031" - https://www.reportlinker.com/p06291564/?utm_source=GNW Where is the largest and fastest growing market for stem cell therapy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The stem cell therapy market global report answers all these questions and many more. The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market.It traces the markets historic and forecast market growth by geography.

It places the market within the context of the wider stem cell therapy market; and compares it with other markets.

The report covers the following chapters Executive Summary The executive summary section of the report gives a brief overview and summary of the report. Report Structure This section gives the structure of the report and the information covered in the various sections. Introduction The introduction section of the report gives brief introduction about segmentation by geography, by type, by cell source, by end-user, and by application. Market Characteristics The market characteristics section of the report defines and explains the stem cell therapy market. This section also defines and describes goods and related services covered in the report. Trends And Strategies This section describes the major trends shaping the global stem cell therapy market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities. Impact of COVID-19 This section describes the impact of COVID-19 on the stem cell therapy market. Global Market Size And Growth This section contains the global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods. Regional Analysis This section contains the historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values and growth and market share comparison by region. Segmentation This section contains the market values (2016-2031) and analysis for different segments. Regional Market Size and Growth This section contains the regions market size (2021), historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values, and growth and market share comparison of countries within the region.This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.

The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies. Competitive Landscape This section covers details on the competitive landscape of the global stem cell therapy market, estimated market shares and company profiles for the leading players. Key Mergers And Acquisitions This section gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years. Market Opportunities And Strategies This section includes market opportunities and strategies based on findings of the research.This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets.

It gives an understanding of where there is significant business to be gained by competitors in the next five years. Conclusions And Recommendations This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for stem cell therapy providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups. Appendix This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope Markets Covered: 1) By Type: Allogeneic Stem Cell Therapy; Autologous Stem Cell Therapy 2) By Cell Source: Adult Stem Cells; Induced Pluripotent Stem Cells; Embryonic Stem Cells 3) By Application: Musculoskeletal Disorders and Wounds & Injuries; Cancer; Autoimmune Disorders; Others 4) By End-Users: Hospitals And Clinics; Research Centers; Others

Companies Mentioned: Smith & Nephew Plc; Fujifilm Holding Corporation; Thermo Fisher Scientific Inc.; Takara Bio Inc; MEDIPOST Co., Ltd.

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; stem cell therapy indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market research findings. Benchmark performance against key competitors. Utilize the relationships between key data sets for superior strategizing. Suitable for supporting your internal and external presentations with reliable high-quality data and analysis. Read the full report: https://www.reportlinker.com/p06291564/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Read the rest here:
Stem Cell Therapy Global Market Opportunities And Strategies To 2031 - Yahoo Finance

Confocal Microscope Market 2022 Analysis Trend, Applications, Growth, and Forecast to 2030 | Save 30% on this report – Taiwan News

Global Confocal Microscope Market is valued at approximately USD $million in 2021 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2022-2028.

The confocal microscope is a type of widefield fluorescence+ microscopy that produces high-resolution pictures of materials stained with fluorescent probes. Due to their tremendous benefits in image resolution, commercially made laser scanning confocal microscopes have achieved enormous popularity across the world. Because it allows photographs to be free of out-of-focus information, the method has acquired significant adoption in molecular imaging.

Download Free Sample of This Strategic Report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5794

Rising incidences of Microbial Keratitis and rising demand for Confocal Microscopy in the diagnosis of ophthalmic conditions have led to the adoption of Confocal Microscopes across the forecast period. In 2017, the Indian Department of Biotechnology published a guideline for stem cell and regenerative medicine that includes fundamental biology of all adult stem cells, early and late translational research, and the development of gene editing technologies for therapeutic applications.

Furthermore, growing number of collaborations among several prominent players to develop new and high-end products, propel the market opportunities for upcoming years. A partnership between India and Japan has been developed to assist stem cell and regenerative medicine research. Indian researchers will receive training at Kyoto Universitys Center for iPS Cell Research and Applications (CiRA). However, high price of Microscopes and lack of skilled professionals impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Confocal Microscope Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the market share globally owing to factors such as huge investment in the research and development activities and rising prevalence of eye diseases. However, Asia Pacific is expected to be the fastest growing region due to rising demand for diagnostic centers and increasing number of healthcare facilities.

SPECIAL OFFER (Avail an Up-to 30% discount on this report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5794

Major market players included in this report are:

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:

Access full Report Description, TOC, Table of Figure, Chart, etc :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5794

By Type:

Multi-Photon Microscopy

Confocal Disk Spinning

By End-user:

Hospitals

Diagnostic Laboratories

Academics & Research Institute

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Access Full Report, here:-https://reportocean.com/industry-verticals/sample-request?report_id=bw5794

About Report Ocean: We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us: Report Ocean: Email:sales@reportocean.com Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE) Website:https://www.reportocean.com/

Read more here:
Confocal Microscope Market 2022 Analysis Trend, Applications, Growth, and Forecast to 2030 | Save 30% on this report - Taiwan News

BreakPoint: Is aging a ‘disease’ and other bioethical questions for Christians – Chattanooga Times Free Press

According to the writer of Proverbs, "death and life are in the power of the tongue." So is cultural change, which most often comes with efforts to change language use and the definitions of words. For example, Harvard Medical molecular biologist David Sinclair is combining innovation in the lab with innovation in language. In a recent CNN article, one of Sinclair's financial backers described the goal of his research as changing the definition of the word "aging." He wants to "make aging a disease."

Sinclair claims to have successfully interrupted the aging process in mice by turning adult cells back into stem cells. Some animals are designed with a similar capability, albeit in a more limited way think, for example, of an octopus regrowing a leg that has been cut off. Using that same idea, what Sinclair calls an "ancient regeneration system," he hopes to regenerate cells that deteriorate with age. Already, he has been able to repair ocular cells in older mice, allowing them to recover their "youthful" eyesight.

His ultimate aim, of course, is to develop anti-aging therapies for humans. Though some concern has been directed toward the safety of Sinclair's process, what goes largely unquestioned in media coverage is Sinclair's chief aim. In other words, as so much medical ethics goes these days, if we can do it, then we should.

Medical ethics from a Christian worldview perspective is not that simple.

Whenever Christians can affirm aspects of work like David Sinclair's, which attempts to overcome the consequences of the fall, we should. The Bible teaches that death is an enemy, and that humans were not made to die. And humans should recognize that the ingenuity and passion for exploration that often inspires medical progress are God-given.

To accuse people like Sinclair of "playing God," as if that were an insult, is not helpful. After all, according to Genesis 1 and 2, human beings were created by God to, in a sense, "play God." We are not to pretend that we are God, of course, but he did gift us with the ability to work alongside him to accomplish his purposes for the world he made. After the fall, he promises to eventually restore his creation, so our work alongside him continues. The mandate to build and create, tending the garden of his world, is to be done within the moral limits that reflect his character and how he created the world.

Within this framework, causing or hastening death is a great evil, but so can be attempts to avoid death "at all costs." Jesus' own death was an act of unprecedented evil but also only fully understood in the context of his obedience to the Father's will. Jesus lay down his life, and many Christians have followed in his footsteps. Thus, there are certain moral goods such as the will of God that are higher than avoiding death.

Keeping these sorts of things straight is essential to ethically pursuing and employing technologies, like those that promise to "reverse aging." In his book "Bioethics: A Primer for Christians," bioethicist and theologian Gilbert Meilaender counsels Christians to view the freedom to pursue medical progress not as freedom from restraints, such as death. Instead, we should consider ourselves free to work alongside God imitating him on the path he set out for human flourishing. This will mean, very often in fact, not doing (as God described the men who built the tower of Babel) "whatever comes into our minds to do."

Meilaender counsels Christians to fight the temptation to use medicine not merely as a way to care for our bodies but from the desire to control them. If the chief end of medical research and practice is to live on our own terms, we will inevitably make moral compromises along the way. It was the serpent who promised Eve that she could live as she wished but evade death, which was not only a lie but not sufficient justification for attempting to usurp the authority that only belongs to God.

The goal of medical research and practice should be to help people flourish in the bodies, times, places and limits that God has given us. From this beginning, Meilaender suggests that the "principle" which should "govern Christian compassion" is not to "minimize suffering," but to "maximize care."

Our purpose is not to avoid suffering or even death at all costs despite that they are effects of the fall we are called to oppose. Rather, we take into account that in God's mercy, even our suffering can be redeemed for good. We lament the hard realities of our fallen world, and we seek to understand them within the larger context of creation and resurrection. Thus, we know that death is not the end of life, nor is life only a prerequisite to death.

From BreakPoint, July 8, 2022; reprinted by permission of the Colson Center, breakpoint.org.

Visit link:
BreakPoint: Is aging a 'disease' and other bioethical questions for Christians - Chattanooga Times Free Press

Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering.

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.

iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Other applications of iPSCs include their use as research products, as well as their integration into 3D bioprinting, tissue engineering, and clean meat production. Technology allowing for the mass-production and differentiation of iPSCs in industrial-scale bioreactors is also advancing at breakneck speed.

iPSC Derived Clinical Trials

The first clinical trial using iPSCs started in 2008, and today, that number has surged worldwide. Most of the current clinical trials do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest.

The therapeutic applications of induced pluripotent stem cells (iPSCs) have also surged in recent years. Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and formal clinical trials worldwide.

Key Topics Covered:

1. Report Overview

2. Introduction

3. Current Status of iPSC Industry

3.1 Progress Made in Autologous Cell Therapy Using iPSCs

3.2 Manufacturing Timeline for Autologous iPSC-Derived Cell Products

3.3 Cost of iPSC Production

3.4 Automation in iPSC Production

3.5 Allogeneic iPSCs Gaining Momentum

3.6 Share of iPSC-Based Research Within the Overall Stem Cell Industry

3.7 Major Focus Areas of iPSC Companies

3.8 Commercially Available iPSC-Derived Cell Types

3.9 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays

3.10 Currently Available iPSC Technologies

4. History of Induced Pluripotent Stem Cells (iPSCs)

5. Research Publications on iPSCs

6. iPSC: Patent Landscape Analysis

6.1 Legal Status of iPSC Patents

6.2 Patents by Assignee Organization Type

6.3 Ownership of Patent Families by Assignee Type

6.4 Top Inventors of iPSC Patents

6.5 Top Ten iPSC Inventors

6.6 Most Cited Five iPSC Patents

6.7 Leading Patent Filing Jurisdictions

6.8 Number of Patent Families by Year of Filing

6.9 Patents Representing Different Disorders

6.10 iPSC Patents on Preparation Technologies

6.11 Patents on Cell Types Differentiated from iPSCs

6.12 Patent Application Trends Disease-Specific Technologies

7. iPSC: Clinical Trial Landscape

7.1 Literature and Database Search

7.2 Number of iPSC Clinical Trials by Year

7.3 iPSC Study Designs

7.4 iPSC-Based Clinical Trials With Commercialization Potential

8. Research Funding for iPSCs

8.1 Value of NIH Funding for iPSC Research

8.2 Partial List of NIH Funded iPSC Research Projects in 2022

9. M&A, Collaborations & Funding Activities in iPSC Sector

10. Generation of Induced Pluripotent Stem Cells: An Overview

10.1 Reprogramming Factors

10.2 Integrating iPSC Delivery Methods

10.3 Non-Integrative Delivery Systems

10.4 Comparison of Delivery Methods for Generating iPSCs

10.5 Genome Editing Technologies in iPSC Generation

11. Human iPSC Banking

11.1 Cell Sources for iPSC Banking

11.2 Reprogramming Methods Used in iPSC Banking

11.3 Factors Used in Reprogramming in Different Banks

11.4 Workflow in iPSC Banks

11.5 Existing iPSC Banks

12. Biomedical Applications of iPSCs

12.1 iPSCs in Basic Research

12.2 iPSCs in Drug Discovery

12.3 iPSCs in Toxicology Studies

12.4 iPSCs in Disease Modeling

12.5 iPSCs in Cell-Based Therapies

12.6 Other Novel Applications of iPSCs

12.7 iPSCs in Animal Conservation

13. Market Overview

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/mg6l5h

Go here to read the rest:
Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -...